Protocol Ledger

NCT07393282 · Phase III · RECRUITING

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Interventional Phase III clinical trial protocol NCT07393282 sponsored by Regeneron Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-21 Enrollment: 270 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07393282
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)270 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07393282
Protocol FieldVerified Registry Value
NCT IdentifierNCT07393282
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment270 participants (ESTIMATED)
Registered Start Date2026-05-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07393282
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI